- Alvotech tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies í New York dagana 5.-6. júní 2024
- Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
- Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
- Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu
- Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunni Simlandi í Bandaríkjunum
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
- Alvotech S.A. Annual General Meeting to be held June 7, 2024
- Aðalfundur Alvotech S.A. boðaður 7. júní 2024
More ▼
Key statistics
As of last trade Alvotech SA (Z45:FRA) traded at 11.90, -30.81% below its 52-week high of 17.20, set on Feb 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.20 |
---|---|
High | 12.25 |
Low | 11.90 |
Bid | 12.30 |
Offer | 13.45 |
Previous close | 11.45 |
Average volume | 276.86 |
---|---|
Shares outstanding | 302.73m |
Free float | 108.49m |
P/E (TTM) | -- |
Market cap | 4.20bn USD |
EPS (TTM) | -2.05 USD |
Data delayed at least 15 minutes, as of Jun 03 2024 14:29 BST.
More ▼